| Sacituzumab govitecan in metastatic triple-negative breast cancer A Bardia, SA Hurvitz, SM Tolaney, D Loirat, K Punie, M Oliveira, A Brufsky, ... New England journal of medicine 384 (16), 1529-1541, 2021 | 1211 | 2021 |
| Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple … EA Mittendorf, H Zhang, CH Barrios, S Saji, KH Jung, R Hegg, A Koehler, ... The Lancet 396 (10257), 1090-1100, 2020 | 948 | 2020 |
| A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer A Bassez, H Vos, L Van Dyck, G Floris, I Arijs, C Desmedt, B Boeckx, ... Nature medicine 27 (5), 820-832, 2021 | 526 | 2021 |
| Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program F Cardoso, JMS Bartlett, L Slaets, CHM Van Deurzen, ... Annals of Oncology 29 (2), 405-417, 2018 | 401 | 2018 |
| Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer A Bardia, SM Tolaney, K Punie, D Loirat, M Oliveira, K Kalinsky, A Zelnak, ... Annals of Oncology 32 (9), 1148-1156, 2021 | 253 | 2021 |
| LBA17 ASCENT: a randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple … A Bardia, SM Tolaney, D Loirat, K Punie, M Oliveira, HS Rugo, A Brufsky, ... Annals of Oncology 31, S1149-S1150, 2020 | 101 | 2020 |
| Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative … V Diéras, R Weaver, SM Tolaney, A Bardia, K Punie, A Brufsky, HS Rugo, ... Cancer Research 81 (4_Supplement), PD13-07-PD13-07, 2021 | 83 | 2021 |
| Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast V Geldhof, LPMH de Rooij, L Sokol, J Amersfoort, M De Schepper, ... Nature communications 13 (1), 5511, 2022 | 80 | 2022 |
| Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer K Van Baelen, T Geukens, M Maetens, V Tjan-Heijnen, CJ Lord, S Linn, ... Annals of Oncology 33 (8), 769-785, 2022 | 78 | 2022 |
| Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis E De Azambuja, M Brandão, H Wildiers, A Laenen, S Aspeslagh, ... ESMO open 5 (5), e000947, 2020 | 75 | 2020 |
| Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor … A Bardia, HS Rugo, SM Tolaney, D Loirat, K Punie, M Oliveira, A Brufsky, ... Journal of Clinical Oncology 42 (15), 1738-1744, 2024 | 69 | 2024 |
| Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta … M Tagliamento, E Agostinetto, M Bruzzone, M Ceppi, KS Saini, ... Critical reviews in oncology/hematology 163, 103365, 2021 | 68 | 2021 |
| Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine … T van Cann, T Loyson, A Verbiest, PM Clement, O Bechter, L Willems, ... Supportive Care in Cancer 26, 869-878, 2018 | 65 | 2018 |
| Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer HS Rugo, SM Tolaney, D Loirat, K Punie, A Bardia, SA Hurvitz, ... NPJ Breast Cancer 8 (1), 98, 2022 | 64 | 2022 |
| Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab T Loyson, T Van Cann, P Schöffski, PM Clement, O Bechter, I Spriet, ... Acta Clinica Belgica 73 (2), 100-109, 2018 | 64 | 2018 |
| Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis LA Carey, D Loirat, K Punie, A Bardia, V Diéras, F Dalenc, JR Diamond, ... NPJ Breast Cancer 8 (1), 72, 2022 | 61 | 2022 |
| Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer E Agostinetto, A Losurdo, G Nader-Marta, A Santoro, K Punie, R Barroso, ... Expert opinion on investigational drugs 31 (6), 567-591, 2022 | 61 | 2022 |
| The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration S Banerjee, KHJ Lim, K Murali, K Kamposioras, K Punie, C Oing, ... ESMO open 6 (2), 100058, 2021 | 59 | 2021 |
| Secondary prevention in hereditary breast and/or ovarian cancer syndromes other than BRCA C Piombino, L Cortesi, M Lambertini, K Punie, G Grandi, A Toss Journal of Oncology 2020 (1), 6384190, 2020 | 52 | 2020 |
| Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape E Adams, H Wildiers, P Neven, K Punie ESMO open 6 (4), 100204, 2021 | 48 | 2021 |
